Keith Underwood - Profile and Investment Details

Investor Profile

Keith Underwood is a Venture Capital based in Phoenix, Arizona, United States with a diverse investment portfolio that includes companies such as Priothera, Spruce Biosciences, BONESUPPORT, Arpida AG, Renovis, Aprea, Immune Targeting Systems, Glionova, LTB4 Sweden, ChemoCentryx, Oncos Therapeutics, Gyros, PTC Therapeutics, Precirix, Renovo, Hybrigenics, GenSight Biologics, OraPharma Inc. (acquired by JNJ), Pulmonx, Cardoz, Biolipox, InCarda Therapeutics, Jerini, Orexo, Nexstim, Five Prime Therapeutics, BeneChill, Modus Therapeutics, Wilson Therapeutics, Algeta, BioStratum, Alba Therapeutics, Aro Biotherapeutics, Carisma Therapeutics, Actelion Pharmaceuticals, Idea, Pharmion, Strongbridge Biopharma, CoreValve, Dynavax Technologies, SpineVision, Ultragenyx Pharmaceutical, FerroKin Biosciences, Resistentia Pharmaceuticals, CytosDoctrin, Rainier Therapeutics, Sopherion Therapeutics, Lumavita, Oncorena, Tisbury Pharmaceuticals, Nucleonics, Vivet Therapeutics, Altimmune, Fusion Pharmaceuticals, Bionaut Pharmaceuticals, OxThera, Tengion, . Over time, Keith Underwood has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Keith Underwood is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Hospitals, Wellness, Women Founded, Outpatient Care, Healthcare Innovation, Life Science, Software, Biotechnology, Clinical Trials, Consulting, Health Diagnostics, Medical, B2B, Therapeutics, Pharmaceuticals, Service Industry may find it worthwhile to explore potential connections with Keith Underwood, as their portfolio suggests a familiarity and interest in this area.

Understanding Keith Underwood’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.